Saravut J. Weroha

712 total citations
19 papers, 349 citations indexed

About

Saravut J. Weroha is a scholar working on Molecular Biology, Oncology and Reproductive Medicine. According to data from OpenAlex, Saravut J. Weroha has authored 19 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Reproductive Medicine. Recurrent topics in Saravut J. Weroha's work include Ovarian cancer diagnosis and treatment (5 papers), Cancer Genomics and Diagnostics (4 papers) and Endometrial and Cervical Cancer Treatments (3 papers). Saravut J. Weroha is often cited by papers focused on Ovarian cancer diagnosis and treatment (5 papers), Cancer Genomics and Diagnostics (4 papers) and Endometrial and Cervical Cancer Treatments (3 papers). Saravut J. Weroha collaborates with scholars based in United States, China and United Kingdom. Saravut J. Weroha's co-authors include Thanyanan Reungwetwattana, Julian R. Molina, Xiaonan Hou, William A. Cliby, Qing Zhang, Haojie Huang, Dejie Wang, Yunqian Pan, Qiang Wu and Liguo Wang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

Saravut J. Weroha

18 papers receiving 345 citations

Peers

Countries citing papers authored by Saravut J. Weroha

Since Specialization

Citations

This map shows the geographic impact of Saravut J. Weroha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saravut J. Weroha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saravut J. Weroha more than expected).

Fields of papers citing papers by Saravut J. Weroha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saravut J. Weroha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saravut J. Weroha. The network helps show where Saravut J. Weroha may publish in the future.

Co-authorship network of co-authors of Saravut J. Weroha

This figure shows the co-authorship network connecting the top 25 collaborators of Saravut J. Weroha. A scholar is included among the top collaborators of Saravut J. Weroha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saravut J. Weroha. Saravut J. Weroha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Phase II clinical trial of PLX038 in patients with platinum resistant ovarian, primary peritoneal and fallopian tube cancer. 2024 ·Journal of Clinical Oncology ·Andrea E. Wahner Hendrickson, Nathan R. Foster, (unknown), (unknown), (unknown), Matthew S. Block, Aminah Jatoi, Saravut J. Weroha, Grace M. Choong, Siddhartha Yadav, (unknown), Gary W. Ashley, P. Langecker, Daniel V. Santi, Scott H. Kaufmann	1
2	Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator's choice of chemotherapy in FRα-positive, platinum-resistant ovarian cancer 2024 ·Gynecologic Oncology ·Gottfried E. Konecny, Kathleen N. Moore, Coriolan Lebreton, Saravut J. Weroha, Margarita Romeo, (unknown), Nicoletta Colombo, David M. O’Malley, Lan Coffman, A. Roszak, Ronnie Shapira‐Frommer, Roy Lalisang, David Cibula, (unknown), (unknown), James Stec, Lingling Li, Michael Method, (unknown), Toon Van Gorp	1
3	A phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) nano-immunoconjugate therapy for metastatic gynecological malignancies: MC1371 (NCT02020707) (1308) 2023 ·Gynecologic Oncology ·Matthew S. Block, (unknown), Vera J. Suman, Wendy K. Nevala, (unknown), Jill M. Schimke, Carrie Strand, Gretchen Glaser, (unknown), Aminah Jatoi, (unknown), Amanika Kumar, Carrie Langstraat, Andrea Wahner Hendrickson, Saravut J. Weroha, Joel M. Reid, Svetomir N. Markovic	1
4	Single cell multiomic profiling of high-grade serous carcinoma. 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), Wazim Mohammed Ismail, Amelia Mazzone, Xiaonan Hou, Saravut J. Weroha, Alexandre Gaspar‐Maia	0
5	Abstract 4724: Single cell multiomic profiling of high-grade serous carcinoma 2023 ·Cancer Research ·(unknown), Wazim Mohammed Ismail, Amelia Mazzone, (unknown), (unknown), (unknown), Xiaonan Hou, Nagarajan Kannan, Ann L. Oberg, Scott H. Kaufmann, Saravut J. Weroha, Alexandre Gaspar‐Maia	1
6	Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naïve advanced solid tumors. 2023 ·Journal of Clinical Oncology ·Benedito A. Carneiro, Howard Safran, J. Thaddeus Beck, Omid Hamid, Alexander I. Spira, P. Savvides, Martin Gutierrez, Yujie Zhao, James L. Abbruzzese, Jeffrey P. Ward, Saravut J. Weroha, (unknown), (unknown), William E. Pierceall, Athanasia Skoura, Jenny Zheng, Kenneth A. Kern, Jacob Thomas, Rafael Santana-Dávila	7
7	Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer 2022 ·Nature Communications ·Donglin Ding, Rongbin Zheng, Ye Tian, Rafael E. Jiménez, Xiaonan Hou, Saravut J. Weroha, Liguo Wang, Lei Shi, Haojie Huang	9
8	Safety and efficacy of etigilimab in combination with nivolumab in select recurrent/advanced solid tumors. 2022 ·Journal of Clinical Oncology ·Meredith McKean, Ecaterina E. Dumbrava, Omid Hamid, Priscilla Merriam, Niharika B. Mettu, Justin Call, Ann M. Kapoun, Jennifer Lucas, Mahesh Seetharam, Ulka N. Vaishampayan, Saravut J. Weroha, Suba Krishnan, Angela George	2
9	Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer 2021 ·Cell Death and Disease ·Dongyan Liu, Xiaonan Hou, (unknown), Valentina Zanfagnin, Yunjian Li, Cristina Correia, Zhiyang Zhao, Chenggang Zhao, Zhirong Liu, Tao Zhang, Zhiyou Fang, Hongzhi Wang, Chao Xu, Saravut J. Weroha, Scott H. Kaufmann, Haiming Dai	5
10	Generating real-world evidence from unstructured clinical notes to examine clinical utility of genetic tests: use case in BRCAness 2021 ·BMC Medical Informatics and Decision Making ·Yiqing Zhao, Saravut J. Weroha, Ellen L. Goode, Hongfang Liu, Chen Wang	7
11	DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3β and WEE1 2020 ·Molecular Cell ·(unknown), Wei Zhang, Donglin Ding, Zhenlin Huang, Yuqian Yan, William Cao, Yunqian Pan, Xiaonan Hou, Saravut J. Weroha, R. Jeffrey Karnes, Dejie Wang, Qiang Wu, Denglong Wu, Haojie Huang	31
12	EZH 2 cooperates with gain‐of‐function p53 mutants to promote cancer growth and metastasis 2019 ·The EMBO Journal ·Yu Zhao, Liya Ding, Dejie Wang, Zhenqing Ye, Yundong He, Linlin Ma, Runzhi Zhu, Yunqian Pan, Qiang Wu, Kun Pang, Xiaonan Hou, Saravut J. Weroha, (unknown), Roger Coleman, Ilsa M. Coleman, R. Jeffery Karnes, Jun Zhang, Peter S. Nelson, Liguo Wang, Haojie Huang	60
13	The Role of Microbiota in Human Reproductive Tract Cancers 2019 ·(unknown), İsmail Mert, Jun Chen, Xiaonan Hou, Saravut J. Weroha, Nicholas Chia, Heidi Nelson, Andrea Mariani, Marina Walther-António	3
14	Abstract 4768: PARP inhibitor-induced autophagy provides an adaptive mechanism of drug resistance in preclinical models of ovarian cancer 2019 ·Cancer Research ·(unknown), Saravut J. Weroha, Xiaonan Hou, Lan Pang, (unknown), Zhen Lü, Robert C. Bast	2
15	Targeting HER2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy 2018 ·Molecular Oncology ·Faye R. Harris, (unknown), Lin Yang, Xiaonan Hou, Konstantinos Leventakos, Saravut J. Weroha, George Vasmatzis, Irina V. Kovtun	31
16	Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy 2018 ·Gynecologic Oncology ·Lucia Tortorella, Carrie Langstraat, Amy L. Weaver, Michaela E. McGree, Jamie N. Bakkum‐Gamez, Sean C. Dowdy, William A. Cliby, Gary L. Keeney, Mark E. Sherman, Saravut J. Weroha, Andrea Mariani, Karl C. Podratz	13
17	LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer 2018 ·Cancers ·Qing Zhang, Xiaonan Hou, (unknown), (unknown), Saravut J. Weroha, William A. Cliby	44
18	Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC) 2011 ·Clinical Lung Cancer ·Thanyanan Reungwetwattana, Saravut J. Weroha, Julian R. Molina	107
19	ER and PR in Renomedullary Interstitial Cells During Syrian Hamster Estrogen-Induced Tumorigenesis: Evidence for Receptor-Mediated Oncogenesis 2001 ·Endocrinology ·Jonathan J. Li, Saravut J. Weroha, (unknown), Ossama Tawfik, Xiaoying Hou, Sara Antonia Li	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact